on Xlife Sciences AG (isin : CH0461929603)
Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH
Zurich, 27th of May 2024: Xlife Sciences AG announced the merger of its portfolio company, palleos healthcare GmbH, with OCT Clinical GmbH. This merger aims to form a leading entity in clinical research.
palleos healthcare, a Germany-based contract research organization (CRO) focused on oncology, and OCT Clinical, a full-service CRO, have completed their merger following the signing of the contract on May 24, 2024.
Combining the strengths of both companies, the merger positions them to offer comprehensive services globally. With palleos healthcare operating primarily in Western and Central Europe and OCT Clinical in Eastern Europe, the new entity will now serve over 300 million people and will be branded as palleos healthcare.
Dr. Philip Räth, Managing Director of palleos healthcare, noted the synergistic benefits, while Dmitry Sharov, CEO of OCT Clinical, highlighted the enhanced service capabilities. Oliver R. Baumann, CEO of Xlife Sciences, expressed enthusiasm about the merger's potential to offer better CRO solutions for global markets.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xlife Sciences AG news